- Home
- LCTX vs CHEB Comparison
LCTX vs CHEB Comparison
Compare LCTX & CHEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- CHEB
- Stock Information
- Founded
- LCTX 1990
- CHEB 2024
- Country
- LCTX United States
- CHEB Singapore
- Employees
- LCTX N/A
- CHEB N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- CHEB
- Sector
- LCTX Health Care
- CHEB
- Exchange
- LCTX Nasdaq
- CHEB NYSE
- Market Cap
- LCTX 110.2M
- CHEB 118.7M
- IPO Year
- LCTX N/A
- CHEB 2024
- Fundamental
- Price
- LCTX $0.55
- CHEB $10.08
- Analyst Decision
- LCTX Strong Buy
- CHEB
- Analyst Count
- LCTX 4
- CHEB 0
- Target Price
- LCTX $5.25
- CHEB N/A
- AVG Volume (30 Days)
- LCTX 3.9M
- CHEB 76.3K
- Earning Date
- LCTX 11-14-2024
- CHEB 01-01-0001
- Dividend Yield
- LCTX N/A
- CHEB N/A
- EPS Growth
- LCTX N/A
- CHEB N/A
- EPS
- LCTX N/A
- CHEB N/A
- Revenue
- LCTX $8,719,000.00
- CHEB N/A
- Revenue This Year
- LCTX N/A
- CHEB N/A
- Revenue Next Year
- LCTX $123.52
- CHEB N/A
- P/E Ratio
- LCTX N/A
- CHEB N/A
- Revenue Growth
- LCTX N/A
- CHEB N/A
- 52 Week Low
- LCTX $0.48
- CHEB $9.96
- 52 Week High
- LCTX $1.61
- CHEB $26.25
- Technical
- Relative Strength Index (RSI)
- LCTX 41.03
- CHEB N/A
- Support Level
- LCTX $0.48
- CHEB N/A
- Resistance Level
- LCTX $0.57
- CHEB N/A
- Average True Range (ATR)
- LCTX 0.05
- CHEB 0.00
- MACD
- LCTX 0.01
- CHEB 0.00
- Stochastic Oscillator
- LCTX 48.36
- CHEB 0.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About CHEB CHENGHE ACQUISITION II CO
Chenghe Acquisition II Co is a blank check company.